$FBRX
Forte Biosciences, Inc.

2018 Q1 Form 10-Q Financial Statement

#000156459018013236 Filed on May 11, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q4 2017 Q1
Revenue $0.00 $10.00K $0.00
YoY Change 0.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.420M $2.400M $1.940M
YoY Change 24.74% 77.78% 74.77%
% of Gross Profit
Research & Development $10.44M $8.290M $6.624M
YoY Change 57.55% 25.04% 2.4%
% of Gross Profit
Depreciation & Amortization $95.00K $90.00K $65.00K
YoY Change 46.15% 28.57% 8.33%
% of Gross Profit
Operating Expenses $12.86M $10.70M $8.564M
YoY Change 50.11% 33.95% 12.98%
Operating Profit -$12.85M -$8.553M
YoY Change 50.19% 13.05%
Interest Expense -$30.00K -$150.0K -$520.0K
YoY Change -94.23% -67.39% 18.18%
% of Operating Profit
Other Income/Expense, Net -$34.00K -$520.0K
YoY Change -93.46% 18.18%
Pretax Income -$12.88M -$10.84M -$9.070M
YoY Change 42.01% 28.59% 13.23%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$12.88M -$10.84M -$9.073M
YoY Change 41.96% 28.55% 13.33%
Net Earnings / Revenue -108370.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$9.684M -$8.150M -$7.374M
COMMON SHARES
Basic Shares Outstanding 19.91M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q4 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $74.00M $88.73M $28.89M
YoY Change 156.18% 183.97% -45.09%
Cash & Equivalents $17.79M $35.93M $6.955M
Short-Term Investments $56.21M $52.79M $21.93M
Other Short-Term Assets $3.100M $1.900M $1.200M
YoY Change 158.33% 58.33% -29.41%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $77.10M $90.63M $30.04M
YoY Change 156.67% 179.19% -44.68%
LONG-TERM ASSETS
Property, Plant & Equipment $1.400M $1.217M $734.0K
YoY Change 90.74% 63.8% 46.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $227.0K $3.522M
YoY Change -94.32% -89.43% 120.13%
Total Long-Term Assets $1.600M $1.444M $4.256M
YoY Change -62.41% -50.03% 102.67%
TOTAL ASSETS
Total Short-Term Assets $77.10M $90.63M $30.04M
Total Long-Term Assets $1.600M $1.444M $4.256M
Total Assets $78.70M $92.07M $34.29M
YoY Change 129.49% 160.45% -39.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.800M $1.951M $947.0K
YoY Change 90.07% 17.11% -44.29%
Accrued Expenses $7.900M $8.120M $7.856M
YoY Change 0.56% 49.35% 48.23%
Deferred Revenue $36.00K $36.00K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $7.200M $7.200M $7.200M
YoY Change 0.0% 0.0% 200.0%
Total Short-Term Liabilities $16.90M $17.33M $16.08M
YoY Change 5.13% 20.5% 69.21%
LONG-TERM LIABILITIES
Long-Term Debt $2.000M $3.625M $8.583M
YoY Change -76.7% -64.6% -44.27%
Other Long-Term Liabilities $200.0K $0.00 $100.0K
YoY Change 100.0% -100.0% 0.0%
Total Long-Term Liabilities $2.200M $3.625M $8.583M
YoY Change -74.37% -64.6% -44.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.90M $17.33M $16.08M
Total Long-Term Liabilities $2.200M $3.625M $8.583M
Total Liabilities $19.06M $20.99M $35.80M
YoY Change -46.76% -25.97% 43.21%
SHAREHOLDERS EQUITY
Retained Earnings -$179.8M -$166.9M -$137.1M
YoY Change 31.18% 30.41%
Common Stock $239.6M $238.0M $4.153M
YoY Change 5669.2% 6543.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $59.68M $71.08M -$132.9M
YoY Change
Total Liabilities & Shareholders Equity $78.74M $92.07M $34.29M
YoY Change 129.6% 160.45% -39.2%

Cashflow Statement

Concept 2018 Q1 2017 Q4 2017 Q1
OPERATING ACTIVITIES
Net Income -$12.88M -$10.84M -$9.073M
YoY Change 41.96% 28.55% 13.33%
Depreciation, Depletion And Amortization $95.00K $90.00K $65.00K
YoY Change 46.15% 28.57% 8.33%
Cash From Operating Activities -$12.71M -$9.170M -$7.570M
YoY Change 67.87% 18.32% 24.71%
INVESTING ACTIVITIES
Capital Expenditures $220.0K -$320.0K $53.00K
YoY Change 315.09% 3100.0% 29.27%
Acquisitions
YoY Change
Other Investing Activities -$3.440M -$28.08M $3.820M
YoY Change -190.05% -509.93% 25.25%
Cash From Investing Activities -$3.661M -$28.40M $3.770M
YoY Change -197.11% -515.2% 25.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $29.00K $41.00K
YoY Change -29.27% 1266.67%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.771M -1.340M 5.240M
YoY Change -133.8% -157.51% -1906.9%
NET CHANGE
Cash From Operating Activities -12.71M -9.170M -7.570M
Cash From Investing Activities -3.661M -28.40M 3.770M
Cash From Financing Activities -1.771M -1.340M 5.240M
Net Change In Cash -18.14M -38.91M 1.440M
YoY Change -1359.72% -2840.14% -142.99%
FREE CASH FLOW
Cash From Operating Activities -$12.71M -$9.170M -$7.570M
Capital Expenditures $220.0K -$320.0K $53.00K
Free Cash Flow -$12.93M -$8.850M -$7.623M
YoY Change 69.59% 14.34% 24.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19912143
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19882551
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19882551
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
92073000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
71082000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8553000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
59678000
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78739000
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19912143
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-166929000
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179809000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-9073000
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
239575000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19905871
CY2018Q1 us-gaap Licenses Revenue
LicensesRevenue
9000
CY2017Q1 us-gaap Licenses Revenue
LicensesRevenue
11000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
12855000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12846000
CY2018Q1 us-gaap Interest Income Other
InterestIncomeOther
315000
CY2017Q1 us-gaap Interest Income Other
InterestIncomeOther
37000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9074000
CY2018Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
349000
CY2017Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
616000
CY2017Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-59000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-34000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-520000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-12880000
CY2018Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-74000
CY2017Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-1000
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12954000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.11
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
20000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
36000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Liabilities
Liabilities
20991000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
238025000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-34000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
27000
CY2018Q1 us-gaap Liabilities
Liabilities
19061000
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
20000
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-108000
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
160000
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2207747
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1521000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
529000
CY2018Q1 us-gaap Depreciation
Depreciation
95000
CY2017Q1 us-gaap Depreciation
Depreciation
65000
CY2018Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
147000
CY2017Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
147000
CY2018Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
46000
CY2017Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-1000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1223000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-19000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-179000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1077000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-293000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1895000
CY2018Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-9000
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-11000
CY2018Q1 toca Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
160000
CY2018Q1 toca Increase Decrease In Deferred Grant Funding
IncreaseDecreaseInDeferredGrantFunding
-1000
CY2017Q1 toca Increase Decrease In Deferred Grant Funding
IncreaseDecreaseInDeferredGrantFunding
-3000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12708000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7567000
CY2018Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
9087000
CY2017Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
13553000
CY2018Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
12528000
CY2017Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
9749000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
220000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
53000
CY2017Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
20000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-3661000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
3771000
CY2017Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
7338000
CY2018Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1800000
CY2017Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1800000
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
41000
CY2017Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
338000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-1771000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5241000
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-18140000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1445000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5510000
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6955000
CY2017Q1 toca Deferred Equity Issuance Costs Incurred But Not Yet Paid
DeferredEquityIssuanceCostsIncurredButNotYetPaid
1013000
CY2018Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
45000
CY2017Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
27000
CY2017Q4 toca Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
2809000
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company&#8217;s financial statements are prepared in accordance with accounting principles generally accepted in the United States (GAAP), which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and expenses and related disclosures during the reporting period. Significant estimates in the Company&#8217;s financial statements relate to clinical trial accruals, the valuation of equity awards, and the development period used for license revenue recognition. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results may differ from these estimates under different assumptions or conditions.</p></div>
CY2018Q1 us-gaap Initial Offering Period
InitialOfferingPeriod
April 19, 2017
CY2017Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
86900000
CY2018Q1 toca Working Capital
WorkingCapital
60200000
CY2018Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2018Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
63000
CY2017Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
72000
CY2018Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
36000
CY2017Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
36000
CY2018Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2017Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3428585
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8164903
CY2018Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
56312000
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
52823000
CY2018Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
107000
CY2018Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
56205000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
52792000
CY2018Q1 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
0
CY2018Q1 toca Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
3955000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2489000
CY2018Q1 toca Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
1310000
CY2017Q4 toca Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
1536000
CY2018Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
246000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
276000
CY2018Q1 toca Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
136000
CY2017Q4 toca Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
104000
CY2018Q1 us-gaap Interest Payable Current
InterestPayableCurrent
65000
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
77000
CY2018Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
802000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
829000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1521000
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29000
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-74000
CY2018Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4277756
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1521000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
529000

Files In Submission

Name View Source Status
0001564590-18-013236-index-headers.html Edgar Link pending
0001564590-18-013236-index.html Edgar Link pending
0001564590-18-013236.txt Edgar Link pending
0001564590-18-013236-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
toca-10q_20180331.htm Edgar Link pending
toca-20180331.xml Edgar Link completed
toca-20180331.xsd Edgar Link pending
toca-20180331_cal.xml Edgar Link unprocessable
toca-20180331_def.xml Edgar Link unprocessable
toca-20180331_lab.xml Edgar Link unprocessable
toca-20180331_pre.xml Edgar Link unprocessable
toca-ex107_198.htm Edgar Link pending
toca-ex311_7.htm Edgar Link pending
toca-ex312_6.htm Edgar Link pending
toca-ex321_8.htm Edgar Link pending